Efficacy in MDD was established using immediate-release and/or sustained-release bupropion formulations.
Efficacy was assessed using the Hamilton Depression Rating Scale (HAMD) total score, HAMD depressed mood item, Clinical Global Impressions Severity and Improvement measures (CGI-S and CGI-I), and the Montgomery-Asberg Depression Rating Scale (MADRS).1
WELLBUTRIN bioequivalence has been established across immediate-, sustained-, and extended-release formulations.1
Three 4- to 6-month placebo-controlled trials in patients with seasonal major depressive disorder (300 mg daily dose).1,6
Combined patient population: WELLBUTRIN XL, n=534; placebo, n=508.6